Skip to content

Oliceridine for Postoperative Analgesia in Elderly Abdominal Surgery Patients

Efficacy and Safety of Oliceridine versus Tegileridine for Postoperative Analgesia in Elderly Patients Undergoing Abdominal Surgery: A Single center Prospective, Randomized, Single-Blind, Controlled Trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600125246
Enrollment
Unknown
Registered
2026-05-22
Start date
2026-05-31
Completion date
Unknown
Last updated
2026-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elective laparoscopic abdominal surgery in elderly patients

Interventions

Group Oliceridine:oliceridine 0.3 mg/kg
Group Tegileridine: Tegileridine0.1 mg/kg

Sponsors

Cangzhou Central Hosptial
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Age 65–85 years, regardless of gender; 2. Scheduled for elective laparoscopic abdominal surgery (including laparoscopic cholecystectomy and radical resection for colorectal cancer); 3. American Society of Anesthesiologists (ASA) physical status classification II–III; 4. The patient and their legal representative have been fully informed and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Known hypersensitivity to oliceridine, tegileridine, or any of their excipients; 2. History of opioid abuse or dependence; 3. Use of opioid analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), or other medications that may affect pain assessment within 1 week prior to surgery; 4. Severe respiratory diseases (e.g., acute exacerbation of chronic obstructive pulmonary disease, status asthmaticus); 5. Severe cardiovascular diseases (e.g., congestive heart failure, uncontrolled hypertension, or arrhythmia); 6. Abnormal QTcF interval: >450 ms in males or >470 ms in females; 7. Severe hepatic or renal insufficiency (Child-Pugh class C liver function; eGFR <30 ml/min/1.73m²); 8. Suspected gastrointestinal obstruction, including paralytic ileus; 9. History of psychiatric disorders, cognitive impairment, or inability to express pain accurately; 10. Pregnant or lactating women; 11. Concurrent participation in other clinical trials; 12. Other conditions deemed unsuitable for inclusion by the investigator.

Design outcomes

Primary

MeasureTime frame
Achievement rate of pain score control at 48 h after surgery;

Secondary

MeasureTime frame
Numerical rating scale,NRS;The times and proportion of rescue analgesic medication use within 48 hours after surgery;Total analgesic consumption within 48 h after surgery;Incidence of respiratory depression in the PACU;Incidence of postoperative nausea and vomiting (PONV) within 48 h after surgery;Hemodynamic parameters in the PACU;Length of stay in the Post-Anesthesia Care Unit (PACU);Time to first postoperative ambulation and gastrointestinal function recovery;QoR-15;Length of hospital stay;

Countries

China

Contacts

Public ContactWenbo Sun

Cangzhou Central Hosptial

15103172838@139.com+86 151 0317 2838

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 30, 2026